{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:37:48Z","timestamp":1773801468735,"version":"3.50.1"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T00:00:00Z","timestamp":1528329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0198158","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T13:36:12Z","timestamp":1528378572000},"page":"e0198158","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients"],"prefix":"10.1371","volume":"13","author":[{"given":"Elizabeth","family":"Colston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Grasela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Pat","family":"Bucy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blisse","family":"Vakkalagadda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan J.","family":"Korman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israel","family":"Lowy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,6,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.virol.2014.02.021","article-title":"HIV cure research: advances and prospects","volume":"454\u2013455","author":"CP Passaes","year":"2014","journal-title":"Virology"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11904-010-0066-0","article-title":"Revisiting immune exhaustion during HIV infection","volume":"8","author":"A Khaitan","year":"2011","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"6","key":"ref3","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"EJ Wherry","year":"2011","journal-title":"Nat Immunol"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/QAI.0b013e318289bced","article-title":"Persisting inflammation and chronic immune activation but intact cognitive function in HIV-infected patients after long-term treatment with combination antiretroviral therapy","volume":"63","author":"KK Pedersen","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1365-2249.1999.00806.x","article-title":"Enhanced expression of CTLA-4 (CD152) on CD4+ T cells in HIV infection","volume":"115","author":"K Steiner","year":"1999","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/00002030-200203080-00002","article-title":"CTLA-4 upregulation during HIV infection: association with anergy and possible target for therapeutic intervention","volume":"16","author":"Q Leng","year":"2002","journal-title":"AIDS"},{"issue":"11","key":"ref7","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/ni1515","article-title":"Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction","volume":"8","author":"DE Kaufmann","year":"2007","journal-title":"Nat Immunol"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/QAD.0000000000000562","article-title":"Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma","volume":"29","author":"F Wightman","year":"2015","journal-title":"AIDS"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1053\/j.seminoncol.2010.09.015","article-title":"Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy","volume":"37","author":"A Hoos","year":"2010","journal-title":"Semin Oncol"},{"issue":"8","key":"ref10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"FS Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12180","article-title":"Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma","volume":"1291","author":"JD Wolchok","year":"2013","journal-title":"Ann N Y Acad Sci"},{"issue":"26","key":"ref12","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"C Robert","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"ref13","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1128\/CVI.00498-09","article-title":"Comparison of immunologic assays for detecting immune responses in HIV immunotherapeutic studies: AIDS Clinical Trials Group Trial A5181","volume":"17","author":"BJ Macatangay","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1177\/0194599815606701","article-title":"Bilateral facial palsy following ipilimumab infusion for melanoma","volume":"153","author":"AL Altman","year":"2015","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"15 suppl","key":"ref15","article-title":"Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma","volume":"29","author":"RA Ibrahim","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"e63818","DOI":"10.1371\/journal.pone.0063818","article-title":"A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection","volume":"8","author":"D Gardiner","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5483\/BMBRep.2011.44.4.217","article-title":"Mechanism of T cell exhaustion in a chronic environment","volume":"44","author":"HT Jin","year":"2011","journal-title":"BMB Rep"},{"key":"ref18","first-page":"737389","article-title":"PD-1 blockade in advanced melanoma in patients with hepatitis C and\/or HIV","volume":"2015","author":"D Davar","year":"2015","journal-title":"Case Rep Oncol Med"},{"issue":"7","key":"ref19","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1097\/QAD.0000000000001429","article-title":"Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab","volume":"31","author":"G Le Garff","year":"2017","journal-title":"AIDS"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/infdis\/jix191","article-title":"Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy","volume":"215","author":"CL Gay","year":"2017","journal-title":"J Infect Dis"},{"issue":"8","key":"ref21","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.4049\/jimmunol.180.8.5439","article-title":"Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection","volume":"180","author":"V Cecchinato","year":"2008","journal-title":"J Immunol"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1182\/blood-2006-04-010637","article-title":"CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques","volume":"108","author":"A Hryniewicz","year":"2006","journal-title":"Blood"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/bcp.12323","article-title":"Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma","volume":"78","author":"Y Feng","year":"2014","journal-title":"Br J Clin Pharmacol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0198158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T14:28:55Z","timestamp":1540218535000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0198158"}},"subtitle":[],"editor":[{"given":"Alan","family":"Landay","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,6,7]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0198158","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,7]]}}}